CC	Cervical Cancer
HPV	Human Papillomavirus
LMICs	Low- and Middle-Income Countries
RT	Radiotherapy
LACC	Locally Advanced Cervical Cancer
CCRT	Concurrent Chemoradiotherapy
CFRT	Conventional Fractionated Radiotherapy
IMRT	Intensity-Modulated Radiotherapy
VMAT	Volumetric Modulated Arc Therapy
HFRT	Hypofractionated Radiotherapy
MHRT	Moderately Hypofractionated Radiotherapy
SBRT	Stereotactic Body Radiation Therapy
LQ Model	Linear-Quadratic Model
α/β Ratio	Alpha/Beta Ratio
EQD2	Equivalent Biological Dose in 2 Gy Fractions
OTT	Overall Treatment time
LCR	Local Control Rate
OS	Overall Survival
CTRI	Clinical Trials Registry—India
LNM	Lymph node Metastasis
HDR	High-Dose-Rate Brachytherapy
ICBT	Intracavitary Brachytherapy
GI	Gastrointestinal
GU	Genitourinary
DFS	Disease-Free Survival
SIB	Synchronous Integration Boost
IGABT	Image-Guided Adaptive Brachytherapy
BT	Brachytherapy
FIGO	International Federation of Gynecology and Obstetrics
CCR	Complete Clinical Response
RFS	Recurrence-Free Survival
NCT	National Clinical Trial
3D-CRT	Three-dimensional Conformal Radiation Therapy
QUANTEC	Quantitative Analysis of Normal Tissue Effects in the Clinic
OAR	Organ-at-Risk
2D-EBRT	Two-dimensional External Beam Radiotherapy
ORR	Overall Response rate
ART	Adaptive Radiotherapy
HDR-BT	High-Dose-Rate Brachytherapy
iCBCT	iterative Cone-beam Computed Tomography
CTCAE	Common Terminology Criteria for Adverse Events
RECIST	Response Evaluation Criteria in Solid Tumors
EORTC	European Organization for Research and Treatment of Cancer
PFS	Progression-Free Survival
CRR	Complete Response Rate
LPFS	locoregional Progression-Free Survival
CSS	Disease-Specific Survival
QOL	Quality of Life
CTC	Circulating Tumor Cell
MTD	Maximum Tolerated Dose
MFS	Metastasis-Free Survival
ABC-RT	Accelerated Brachytherapy combined with Hypofractionated Radiotherapy and Concurrent Chemotherapy
LRFS	Local Recurrence-Free Survival
RRFS	Regional Recurrence-Free Survival
HICs	High-Income Countries
DSS	Disease-Specific Survival
INCan	National Institute of Cancerology
RBE	Relative Biological Effectiveness
TIME	Tumor Immune Micr oenvironment